Edgewise Therapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2020 | 51.2% | 51.2% | -13.1% |
| FY2021 | -15.6% | -15.6% | -15.0% |
| FY2022 | -19.5% | -19.5% | -18.4% |
| FY2023 | -31.4% | -31.4% | -29.5% |
| FY2024 | -29.1% | -29.1% | -27.5% |
| FY2025 | -32.1% | -32.1% | -30.4% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2020 | 51.2% | 51.2% | -13.1% |
| FY2021 | -15.6% | -15.6% | -15.0% |
| FY2022 | -19.5% | -19.5% | -18.4% |
| FY2023 | -31.4% | -31.4% | -29.5% |
| FY2024 | -29.1% | -29.1% | -27.5% |
| FY2025 | -32.1% | -32.1% | -30.4% |